Qrons Appoints Dr. Motti Ratmansky as Special Advisor for IND & Clinical Trial Preparations
May 08, 2019 09:00 ET | Qrons Inc.
New York, NY, May 08, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Qrons Inc. (OTC: QRON), an emerging biotechnology company developing advanced stem cell-synthetic hydrogel-based solutions to...
Teneobio Announces US FDA Approval of the Investigational New Drug Application for TNB-383B and the Initiation of Phase I Clinical Studies in Multiple Myeloma Patients
April 29, 2019 08:00 ET | TeneoBio, Inc
NEWARK, Calif., April 29, 2019 (GLOBE NEWSWIRE) -- Teneobio, Inc. and its affiliate TeneoOne, Inc. announced today that their investigational new drug application (IND) for TNB-383B, a bispecific...
Incysus Therapeutics Announces FDA Approval of IND Application for a Novel Gamma-Delta (γδ) T Cell Therapy for Treatment of Patients With Newly-Diagnosed Glioblastoma
April 01, 2019 08:00 ET | Incysus Therapeutics, Inc.
NEW YORK, April 01, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
CURE Logo.png
CURE Pharmaceutical Announces Completion of FDA Pre-IND Review and Clinical Trial Plans for CUREfilm Blue™ for Erectile Dysfunction
March 26, 2019 07:25 ET | Cure Pharmaceutical Holding Corp.
OXNARD, Calif., March 26, 2019 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced it has successfully completed a pre-IND...
20170406 Telix Logo.png
Telix Pharmaceuticals Launches illumet™ Microsite (Kit for the Preparation of 68Ga-PSMA)
January 23, 2019 08:00 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (“Telix Group”, “Company”), a clinical-stage biopharmaceutical company focused on the...
ASLAN Pharmaceuticals Announces IND Submission for ASLAN003 to U.S. FDA and Conclusion of 30-Day Review Period
January 04, 2019 02:00 ET | ASLAN Pharmaceuticals Limited
- ASLAN003 is an orally active, potent inhibitor of DHODH that has the potential to be first-in-class in AML- Positive interim Phase 2a data for ASLAN003 in AML was presented at the 2018 ASH Annual...
TLC Reports Last Patient Last Visit (LPLV) in TLC599 Phase II Trial and FDA Clearance to Commence New Clinical Trials
July 09, 2018 15:01 ET | Taiwan Liposome Company, Ltd.
LPLV marks the final steps toward completion of TLC599 trial for osteoarthritis (OA) painPhase II topline results on-track for 2018 releaseSet to initiate enrollment of US Phase II pharmacokinetic...
Voyager Therapeutics Logo.jpg
Voyager Therapeutics Announces FDA Clearance of Investigational New Drug Application for VY-AADC for Advanced Parkinson’s Disease
January 23, 2018 07:04 ET | Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
aTyr Pharma Announces Poster Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium    
December 21, 2017 08:00 ET | aTyr Pharma, Inc.
SAN DIEGO, Dec. 21, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of immuno-modulatory protein therapeutics to treat...
Orphazyme assumes sponsorship of Phase II/III sIBM trial
December 15, 2017 09:20 ET | ORPHAZYME A/S
Investor newsNo. 01/2017 Orphazyme assumes sponsorship of Phase II/III sIBM trial On December 14, 2017, Orphazyme A/S, University of Kansas Medical Center, and UCL announced that Orphazyme...